Clinical Trial Update: Wild Type p53 Adenovirus for Oral Premalignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a wild-type p53 adenovirus for oral premalignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cancer
• Oral Premalignant Lesions

Drugs mentioned

• wild-type p53 adenovirus (adenoviral p53 gene therapy vector)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mouth Cancer | Phase 1 | Status: TERMINATED